BioLife Solutions (BLFS) Issues Earnings Results

BioLife Solutions (NASDAQ:BLFS) issued its earnings results on Thursday. The medical equipment provider reported $0.04 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.04, Morningstar.com reports. The business had revenue of $5.46 million during the quarter, compared to the consensus estimate of $5.47 million. BioLife Solutions had a return on equity of 8.63% and a net margin of 10.42%. BioLife Solutions updated its FY 2019 guidance to EPS.

BioLife Solutions stock traded up $1.27 during mid-day trading on Friday, reaching $18.96. The stock had a trading volume of 3,235 shares, compared to its average volume of 155,449. BioLife Solutions has a fifty-two week low of $4.85 and a fifty-two week high of $26.35. The stock has a market capitalization of $327.27 million, a PE ratio of -89.17 and a beta of 1.65.

In other BioLife Solutions news, VP Todd Berard sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $12.12, for a total value of $36,360.00. Following the completion of the sale, the vice president now owns 37,583 shares of the company’s stock, valued at $455,505.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Greef Roderick De sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 20th. The shares were sold at an average price of $17.23, for a total value of $172,300.00. Following the completion of the sale, the chief financial officer now directly owns 24,583 shares of the company’s stock, valued at approximately $423,565.09. The disclosure for this sale can be found here. Insiders sold 57,869 shares of company stock valued at $781,532 in the last three months. Insiders own 38.50% of the company’s stock.



A number of institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC boosted its position in shares of BioLife Solutions by 39.0% during the third quarter. Acadian Asset Management LLC now owns 69,361 shares of the medical equipment provider’s stock valued at $1,213,000 after buying an additional 19,456 shares during the last quarter. Vanguard Group Inc boosted its position in BioLife Solutions by 43.1% in the third quarter. Vanguard Group Inc now owns 447,984 shares of the medical equipment provider’s stock worth $7,839,000 after purchasing an additional 134,869 shares during the last quarter. BlackRock Inc. boosted its position in BioLife Solutions by 37.0% in the second quarter. BlackRock Inc. now owns 51,246 shares of the medical equipment provider’s stock worth $585,000 after purchasing an additional 13,846 shares during the last quarter. Vanguard Group Inc. boosted its position in BioLife Solutions by 43.1% in the third quarter. Vanguard Group Inc. now owns 447,984 shares of the medical equipment provider’s stock worth $7,839,000 after purchasing an additional 134,869 shares during the last quarter. Finally, Sandler Capital Management boosted its position in BioLife Solutions by 418.9% in the third quarter. Sandler Capital Management now owns 783,820 shares of the medical equipment provider’s stock worth $13,717,000 after purchasing an additional 632,780 shares during the last quarter. 40.67% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have weighed in on BLFS. BidaskClub upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a report on Friday, March 1st. ValuEngine upgraded BioLife Solutions from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 28th. Zacks Investment Research downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Janney Montgomery Scott upgraded BioLife Solutions to a “buy” rating and set a $5.00 target price for the company in a report on Thursday, December 20th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $17.75.

COPYRIGHT VIOLATION NOTICE: “BioLife Solutions (BLFS) Issues Earnings Results” was reported by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://dakotafinancialnews.com/2019/03/15/biolife-solutions-blfs-issues-earnings-results.html.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Recommended Story: Derivative

Earnings History for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.